Galderma survey finds 47% would consider wrinkle treatments: stock pre-market at EUR 173.95
Published on 10/08/2026 at 08:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Galderma reported new survey findings on menopause-related skin changes on October 7, 2026, while its stock was at EUR 173.95 pre-market at Lang & Schwarz at 8:08 a.m. CEST.
Pre-market price
The Lang & Schwarz price was EUR 173.95 at 8:08 a.m. CEST on October 8, 2026. Bid and ask prices were EUR 173.10 and EUR 174.80, respectively. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Galderma stock.
Survey highlights menopause-related skin concerns
In its October 7 newsroom item, Galderma said its 2026 global survey covered more than 4,300 perimenopausal and menopausal women across five continents. The company said hormonal changes can reduce collagen, elastin and hyaluronic acid, contributing to wrinkles, dryness and loss of firmness.
Galderma said 47% of respondents would consider wrinkle treatments, while 41% would consider hyaluronic acid treatments and 30% would consider biostimulators. The company also said 61% of surveyed women would have acted differently if they had received information about menopause-related skin changes at an earlier age.
Galderma said it has incorporated menopausal status as a standard parameter in all its clinical trials for injectable aesthetics. The company described the initiative as part of a broader effort to improve education and develop more personalized treatment approaches.
